Skip to content


Givinostat (sold under the brand name Duvyzat) is a potential treatment for Duchenne muscular dystrophy. It is a drug from a family of molecules called HDAC (histone deacetylase) inhibitors that aims to restore muscle regeneration, increase muscle mass, and reduce inflammation and scar tissue accumulation. It is manufactured by ITF Pharma Ltd (Italfarmaco Group in the UK). 

Approval process

In March 2024 it was approved by the FDA (U.S. Food and Drug Administration) for use in boys aged 6 and older in the United States. It is not currently licensed in the UK.  Italfarmaco Group is currently applying to the Medicines and Healthcare products Regulatory Agency (MHRA) for a licence. 

If successful, further assessments of clinical and cost-effectiveness by the National Institute for Health and Care Excellence (NICE) and the Scottish Medicines Consortium (SMC) must also be undertaken before a medicine is available to patients on the NHS.

Support and information

Duchenne muscular dystrophy

Duchenne muscular dystrophy is a muscle wasting condition caused by the lack of a protein called dystrophin. It usually affects only boys.


We fund groundbreaking research to learn more about muscle wasting conditions and lead us to new treatments. We’ve already made advances that would have been unthinkable just 10 years ago, and we are determined to go even further and faster.

Our support services

We are here for everyone, but we understand that support isn’t one-size-fits-all. Speak to us. We can tailor our support to meet your unique needs.

Our helpline is open Monday-Thursday 10am-2pm.